Eli Lilly to Acquire AtaiBeckley for $2.8B
Eli Lilly to Acquire AtaiBeckley for about $2.8 billion in cash, plus contingent value rights that could add roughly $1.0 billion. For EU and UK readers, the July 16, 2026 deal is less about a near-term European label and more about how U.S.-priced psychedelic milestones meet MHRA and EMA clinical-trial and controlled-drug reality.
Contents11 sections
Key Takeaways
- Lilly will buy AtaiBeckley for $6.75/share cash (~$2.8B) plus CVRs up to $2.50/share (~$1.0B) tied to BPL-003 and VLS-01 U.S./DEA milestones.
- Lead asset BPL-003 is intranasal mebufotenin (5-MeO-DMT) for treatment-resistant depression, with FDA Breakthrough Therapy Designation and Phase 3 activities started.
- Disclosed CVR triggers are U.S. approval and DEA rescheduling — not EMA CHMP opinion or MHRA marketing authorisation.
- UK Schedule 1 controlled-drug research rules and MHRA clinical-trial reforms remain the practical gate for Europe-facing psychedelic programmes.
Lilly–AtaiBeckley deal at a glance
| Field | Detail |
|---|---|
| Buyer | Eli Lilly and Company (NYSE: LLY) |
| Target | AtaiBeckley Inc. (Nasdaq: ATAI) |
| Upfront | $6.75 per share cash (~$2.8B aggregate equity value) |
| CVR | Up to $2.50/share (~$1.0B); VLS-01 Phase 3 start; U.S. approval + DEA rescheduling of BPL-003 and VLS-01 |
| Lead asset | BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression |
| EU/UK regulatory note | No EMA or MHRA approval claimed in the deal materials; CVR economics are U.S./DEA-linked |
| Expected close | Q3 2026 (stockholder + customary regulatory approvals) |
What did Lilly and AtaiBeckley announce?
On July 16, 2026, Lilly and AtaiBeckley said they had signed a definitive agreement for Lilly to acquire AtaiBeckley. The joint release is on Lilly and AtaiBeckley's PR Newswire release.
AtaiBeckley is advancing rapid-acting neuroplastogens for mental health. Lilly framed the purchase as an expansion of its neuroscience pipeline into treatment-resistant depression and related conditions. The same terms appear in AtaiBeckley's SEC Exhibit 99.1 joint press release.
How is the $2.8B deal structured?
At closing, Lilly will pay $6.75 per share in cash — about $2.8 billion in aggregate equity value. Holders also receive a CVR worth up to $2.50 per share if milestones are met (~$1.0 billion potential). There is no assurance any CVR payment will be made.
Per the filings, CVR cash would pay: (a) $1.00 if a Phase 3 trial of VLS-01 starts before the fourth anniversary of closing; (b) $0.50 upon U.S. approval and DEA rescheduling of BPL-003 before the fifth anniversary; and (c) $1.00 upon U.S. approval and DEA rescheduling of VLS-01 before the seventh anniversary.
The merger agreement is dated July 15, 2026. Closing is expected in the third quarter of 2026, subject to AtaiBeckley stockholder approval and customary conditions, including regulatory clearances. The deal is not subject to a financing condition. See AtaiBeckley's July 16 DEFA14A filing.
Why the CVR design is a U.S. story first
For European capital and access planners, the most important deal detail is what the CVR does not pay on. The disclosed triggers are U.S. regulatory approval and DEA rescheduling, plus a VLS-01 Phase 3 start. They are not framed as EMA marketing authorisation, MHRA approval, or NICE/HTA milestones.
That does not block EU or UK development. It does mean the published economics of Eli Lilly to Acquire AtaiBeckley for $2.8 billion are priced to the U.S. controlled-substance and FDA path first. Any Europe strategy would be incremental to those disclosed CVR terms.
What EU and UK rules shape psychedelic-class programmes?
BPL-003 is a synthetic form of 5-MeO-DMT; VLS-01 is a DMT buccal film; EMP-01 is (R)-MDMA HCl. In the UK, many such compounds sit under Schedule 1 of the Misuse of Drugs Regulations 2001, which imposes the tightest research controls.
The Advisory Council on the Misuse of Drugs has documented Home Office licensing as a material barrier to Schedule 1 research, including psychedelic drugs, and recommended exemptions for clinical studies that already hold MHRA and ethics approvals. See the UK government ACMD barriers-to-research Part 2 report on Schedule 1 controlled drugs.
Separately, MHRA clinical-trial rules are changing. From 28 April 2026, UK trial applications use the amended Medicines for Human Use (Clinical Trials) framework, with combined ethics and licensing review via IRAS. Sponsors planning Europe-facing interventional psychiatry work should track that process alongside any Home Office controlled-drug licences, as set out in GOV.UK MHRA guidance on applying for UK clinical trial approval.
What about EMA authorisation for these assets?
The deal materials do not claim an EMA positive opinion, CHMP recommendation, or EU marketing authorisation for BPL-003, VLS-01, or EMP-01. EU centralised authorisation would be a separate regulatory programme from the U.S. FDA and DEA steps named in the CVR.
For context on how Europe is rewriting the broader medicines framework that would eventually govern such products, see our coverage of the EU Commission and EU drugs agency 2026 drug report and PRAC June 2026 safety highlights.
What remains unproven for Europe?
Phase 3 outcomes for BPL-003 are not in the deal package. No EMA or MHRA approval timeline is disclosed. Whether a two-hour in-clinic model fits EU outpatient psychiatry systems, how HTA bodies would value durability claims, and whether Schedule 1 research reforms land in UK law on a useful timeline all remain open.
Until those paths are disclosed in primary filings, European readers should treat this as a U.S.-anchored M&A event with clear implications for EU/UK trial operations — not as a European launch story.
Related NovaPharma coverage
- U.S. analysis: Lilly to buy AtaiBeckley for $2.8B
- Vanda Pharmaceuticals EMA orphan drug designation opinion
- EU Commission and EU drugs agency 2026 drug report
Frequently Asked Questions
What are the key terms of Eli Lilly to Acquire AtaiBeckley for $2.8 billion?
Lilly will pay $6.75 per share in cash at closing, about $2.8 billion in equity value, plus CVRs of up to $2.50 per share (~$1.0 billion potential) tied to BPL-003 and VLS-01 U.S. development and DEA-linked milestones. Closing is targeted for Q3 2026.
Do the Lilly–AtaiBeckley CVR milestones cover EMA or MHRA approval?
No. As disclosed, CVR cash triggers are U.S.-centric: a VLS-01 Phase 3 start and U.S. regulatory approval plus DEA rescheduling for BPL-003 and VLS-01. Separate EMA or MHRA authorisation paths are not the stated CVR triggers.
Why does the Lilly–AtaiBeckley deal matter for EU and UK psychiatry R&D?
The assets are tryptamine-class neuroplastogens that sit under controlled-drug and clinical-trial rules in Europe. UK Schedule 1 research barriers and MHRA trial reforms shape how similar programmes can run locally, even when deal economics are priced to U.S. approval and DEA rescheduling.
Primary Sources
Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
